Skip to main content
main-content
Top

06-04-2018 | Pediatrics | Review | Article

Identifying Prediabetes and Type 2 Diabetes in Asymptomatic Youth: Should HbA1c Be Used as a Diagnostic Approach?

Journal: Current Diabetes Reports

Authors: Mary Ellen Vajravelu, Joyce M. Lee

Publisher: Springer US

share
SHARE

Abstract

Purpose of Review

Because the incidence of type 2 diabetes and prediabetes in children is rising, routine screening of those at risk is recommended. In 2010, the ADA made the recommendation to include hemoglobin A1c (HbA1c) as a diagnostic test for diabetes, in addition to the oral glucose tolerance test or fasting plasma glucose. Our objective was to assess the pediatric literature with regard to HbA1c test performance and discuss advantages and disadvantages of use of the test for diagnostic purposes.

Recent Findings

HbA1c has a number of advantages, including elimination of the need for fasting, lower variability, assay standardization, and long-term association with future development of diabetes. It also has many drawbacks. It can be affected by a number of non-glycemic factors, including red blood cell turnover, hemoglobinopathies, medications, race, and age. In particular, it performs differently in children compared with adults, generally with lower sensitivity for prediabetes (as low as 0–5% in children vs 23–27% in adults) and lower area under the receiver operating characteristic curve (AUC) (0.53 vs 0.73 for prediabetes), and it has lower efficacy at a higher cost, compared with other tests of glycemia. Finally, HbA1c may perform very differently across diverse populations according to race/ethnicity; in Chinese populations, the proportion of individuals classified with prediabetes based on HbA1c predominates compared with IFG (77% for HbA1c vs 27.7% for IFG), whereas in US populations, it is the opposite (24.8% for HbA1c vs 80.1% for FPG).

Summary

HbA1c is controversial because although it is convenient, it is not a true measure of glycemia. The interpretation of HbA1c results requires a nuanced understanding that many primary care physicians who are ordering the test in greater numbers do not possess. Alternative markers of glycemia may hold promise for the future but are not yet endorsed for use in practice. Further studies are needed to determine appropriate thresholds for screening tests and the long-term impact of screening and identification.
Literature
1.
• Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med. 2017;376(15):1419–29. This study highlights the rising incidence of type 2 diabetes in youth, which was greatest among minority racial and ethnic groups. CrossRefPubMedPubMedCentral
2.
American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000;105(3):671–80. CrossRef
3.
Williams DE, Cadwell BL, Cheng YJ, Cowie CC, Gregg EW, Geiss LS, et al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999-2000. Pediatrics. 2005;116(5):1122–6. CrossRefPubMed
4.
Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159–67. CrossRefPubMed
5.
Savoye M, Caprio S, Dziura J, Camp A, Germain G, Summers C, et al. Reversal of early abnormalities in glucose metabolism in obese youth: results of an intensive lifestyle randomized controlled trial. Diabetes Care. 2014;37(2):317–24. CrossRefPubMedPubMedCentral
6.
Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22(2):345–54. CrossRefPubMed
7.
American Diabetes Association. Type 2 diabetes in children and adolescents.. Diabetes Care 2000;23(3):381–389.
8.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9. CrossRefPubMedCentral
9.
American Diabetes Association. 12. Children and adolescents: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S126–S36.
10.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus*. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183–97. CrossRef
11.
Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care. 2010;33(3):562–8. CrossRefPubMedPubMedCentral
12.
Parrinello CM, Selvin E. Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep. 2014;14(11):548. CrossRefPubMedPubMedCentral
13.
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011:1–25.
14.
Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007;167(14):1545–51. CrossRefPubMed
15.
Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34(1):145–50. CrossRefPubMed
16.
•• Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care. 2017;40(1):16–21. This study provides the first longitudinal evidence of the utility of HbA1c as a predictor of type 2 diabetes when used in American Indian youth. CrossRefPubMed
17.
Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27(7):1761–73. CrossRefPubMed
18.
Sacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA 2014;311(22):2271–2, 2272.
19.
Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697–708. CrossRefPubMedPubMedCentral
20.
Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem. 2011;57(2):344–6. CrossRefPubMed
21.
Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet. 1980;2(8186):141. CrossRefPubMed
22.
Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol. 2004;112(3):126–8. CrossRefPubMed
23.
Hardikar PS, Joshi SM, Bhat DS, Raut DA, Katre PA, Lubree HG, et al. Spuriously high prevalence of prediabetes diagnosed by HbA(1c) in young Indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care. 2012;35(4):797–802. CrossRefPubMedPubMedCentral
24.
Arnold JG, McGowan HJ. Delay in diagnosis of diabetes mellitus due to inaccurate use of hemoglobin A1C levels. J Am Board Fam Med. 2007;20(1):93–6. CrossRefPubMed
25.
Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009;3(3):446–51. CrossRefPubMedPubMedCentral
26.
Meyer LM, Adams JG 3rd, Steinberg MH, Miller IE, Stokes N. Screening for sickle cell trait: the veterans administration National Sickle Cell Program. Am J Hematol. 1987;24(4):429–32. CrossRefPubMed
27.
NGSP. HbA1c Assay Interferences 2017 [Available from: http://​www.​ngsp.​org/​interf.​asp.​
28.
Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528–31. CrossRefPubMedPubMedCentral
29.
Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program. Diabetes Care. 2007;30(10):2453–7. CrossRefPubMedPubMedCentral
30.
Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(5):1689–94. CrossRefPubMed
31.
Cohen RM. A1C: does one size fit all? Diabetes Care. 2007;30(10):2756–8. CrossRefPubMed
32.
Eberhardt MS, Lackland DT, Wheeler FC, German RR, Teutsch SM. Is race related to glycemic control? An assessment of glycosylated hemoglobin in two South Carolina communities. J Clin Epidemiol. 1994;47(10):1181–9. CrossRefPubMed
33.
Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997;260(1):49–64. CrossRefPubMed
34.
Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham offspring study and the National Health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31(10):1991–6. CrossRefPubMedPubMedCentral
35.
Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin a(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011;34(6):1306–11. CrossRefPubMedPubMedCentral
36.
• Ehehalt S, Wiegand S, Korner A, Schweizer R, Liesenkotter KP, Partsch CJ, et al. Diabetes screening in overweight and obese children and adolescents: choosing the right test. Eur J Pediatr. 2017;176(1):89–97. This multicenter observational study of nearly 5,000 overweight and obese youth found that the optimal threshold for identifying diabetes using HbA1c was 6.0%, lower than suggested by current standards. CrossRefPubMed
37.
Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr. 2011;158(6):947–52 e1–3. CrossRefPubMed
38.
Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care. 2000;23(2):187–91. CrossRefPubMed
39.
Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance of A1C for the classification and prediction of diabetes. Diabetes Care. 2011;34(1):84–9. CrossRefPubMed
40.
Brar PC, Mengwall L, Franklin BH, Fierman AH. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. Clin Pediatr. 2014;53:771–776.
41.
Li P, Jiang R, Li L, Li L, Wang Z, Li X, et al. Diagnostic performance of hemoglobin A1c for prediabetes and association with cardiometabolic risk factors in Chinese adolescents without diabetes. J Investig Med. 2012;60(6):888–94. CrossRefPubMed
42.
Tomita M, Kabeya Y, Okada K, Shirai M, Asai S, Katsuki T, et al. Normal glucose tolerance with high HbA1c levels observed in two cases of Hb variants. Diabetol Int. 2010;1(2):104–7. CrossRef
43.
Arakaki RF, Changcharoen B. Glycemic assessment in a patient with HB Leiden and type 2 diabetes. AACE Clin Case Rep. 2016;2(4):e307-e10.
44.
Lee JM, Eason A, Nelson C, Kazzi NG, Cowan AE, Tarini BA. Screening practices for identifying type 2 diabetes in adolescents. J Adolesc Health. 2014;54(2):139–43. CrossRefPubMed
45.
Wu EL, Kazzi NG, Lee JM. Cost-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia. JAMA Pediatr. 2013;167(1):32–9. CrossRefPubMed
46.
Lee JM, Gebremariam A, Wu EL, LaRose J, Gurney JG. Evaluation of nonfasting tests to screen for childhood and adolescent dysglycemia. Diabetes Care. 2011;34(12):2597–602. CrossRefPubMedPubMedCentral
47.
McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care. 2004;27(8):1859–65. CrossRefPubMed
48.
Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011;34(4):960–7. CrossRefPubMedPubMedCentral
49.
Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia—1,5-anhydroglucitol, fructosamine, and glycated albumin. Pediatr Diabetes. 2016;17(3):206–11. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.